Context, ethics and pharmacogenetics

Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences

Volumn 37, Issue 3, 2006, Pages 566-582

  Hedgecoe, Adam M ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Alzheimer's disease; Empirical bioethics; Herceptin; Industry; Pharmacogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ALZHEIMER DISEASE; ARTICLE; BREAST TUMOR; CONFIDENTIALITY; COST BENEFIT ANALYSIS; DOCTOR PATIENT RELATION; ECONOMICS; ETHICS; GENETIC SCREENING; GENETICS; GENOTYPE; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMED CONSENT; INTERVIEW; MEDICAL ETHICS; PHARMACOGENETICS;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; BREAST NEOPLASMS; CONFIDENTIALITY; COST-BENEFIT ANALYSIS; ETHICS, MEDICAL; GENETIC SCREENING; GENETIC TESTING; GENOTYPE; HUMANS; INFORMED CONSENT; INTERVIEWS; INTERVIEWS AS TOPIC; PHARMACOGENETICS; PHYSICIAN-PATIENT RELATIONS;

EID: 33748512370     PISSN: 13698486     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.shpsc.2006.06.003     Document Type: Article

References (67)

1. Akhtar S. Pharmacogenomics: Are pharmacists ready for genotyped prescribing?. The Pharmaceutical Journal 268 (2002) 296-299
2. Anderson W.H., Fitzgerald C.Q., and Monasco P.K. Current and future applications of pharmacogenomics. New Horizons 7 2 (1999) 262-269
3. Anon. Editorial: Pharmacogenomics at work. Nature Biotechnology 16 10 (1998) 885
4. Bazell R. Her-2: The making of Herceptin. a revolutionary treatment for breast cancer (1998), Random House
5. Beauchamp T.L., and Childress J.F. Principles of biomedical ethics. 5th ed. (2001), Oxford University Press, Oxford
6. Beeson D., and Dokusm T. Family values and resistance to genetic testing. In: Hoffmaster B. (Ed). Bioethics in a social context (2000), Temple University Press, Philadelphia 153-179
7. In: Bijker W.E., Hughes T.P., and Pinch T.J. (Eds). The social construction of technical systems (1987), MIT Press, Cambridge, MA
8. In: Bijker W.E., and Law J. (Eds). Shaping technology/building society: Studies in sociotechnical change (1992), MIT Press, Cambridge, MA
9. Brodaty H., Conneally M., Gauthier S., Jennings C., Lennox A., and Lovestone S. Consensus statement on predictive testing for Alzheimer disease. Alzheimer Disease and Associated Disorders 9 4 (1995) 182-187
10. Brushwood D.B. The challenges of pharmacogenomics for pharmacy education, practice, and regulation. In: Rothstein M.A. (Ed). Pharmacogenomics: Social, ethical and clinical dimensions (2003), John Wiley & Sons, New Jersey 207-225
11. Buchanan, A., Califano, A., Kahn, J., McPherson, E., Robertson, J., & Brody, B. (2002). Pharmacogenetics: Ethical and regulatory issues in research and clinical practice. Report of the consortium on pharmacogenetics. Findings and recommendations. http://www.bioethics.umn.edu/News/pharm_report.pdf.
12. Clarke A., English V., Harris H., and Wells F. Report on ethical considerations. International Journal of Pharmaceutical Medicine 15 (2001) 89-94
13. Consortium on Pharmacogenetics (2002). Pharmacogenetics: Ethical and regulatory issues in research and clinical practice report, findings and recommendations. http://www.firstgenetic.net/latest_news/article_16.pdf.
14. DeVries R., and Conrad P. Why bioethics needs sociology. In: DeVries R., and Subedi J. (Eds). Bioethics and society: Constructing the ethical enterprise (1998), Prentice Hall, New Jersey 233-257
15. Emery J., and Hayflick S. The challenges of integrating genetic medicine into primary care. British Medical Journal 322 (2001) 1030-1097
16. Ensom M.H.H., Chang T.K.H., and Patel P. Pharmacogenetics: The therapeutic drug monitoring of the future?. Clinical Pharmacokinetics 40 11 (2001) 783-802
17. European Agency for the Evaluation of Medicinal Products (2000). Report to the CPMP on the EMEA seminar on the use of pharmacogenetics in the drug development process-5 June 2000. London, 27 July 2000. EMEA/CPMP/1483/00 (Available at http://www.emea.eu.int/pdfs/human/regaffair/148300enpdf).
18. Evans W.E., and Jonson J.A. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annual Review of Genomics and Human Genetics 2 (2001) 9-39
19. Farlow M., Gracon S., Hershey L., Lewis K., Sadowsky C., and Dolanureno J. A controlled trial of Tacrine in Alzheimer's disease. Journal of the American Medical Association 268 18 (1992) 2523-2529
20. Farrer L.A., Brin M.F., Elsas L., Goate A., Kennedy J., Mayeux R., Myers R.H., Reilly P., and Risch N.J. Statement on use of Apolipoprotein-E testing for Alzheimer disease. Journal of the American Medical Association 274 20 (1995) 1627-1629
21. Fox R.C., and Swazey J.P. Medical morality is not bioethics: Medical ethics in China and the United States. Perspectives in Biology and Medicine 27 3 (1984) 336-360
22. Ginsburg G.S., and McCarthy J.J. Personalized medicine: Revolutionizing drug discovery and patient care. Trends in Biotechnology 19 12 (2001) 491-496
23. Haimes E. What can the social sciences contribute to the study of ethics? Theoretical, empirical and substantive considerations. Bioethics 16 2 (2002) 89-113
24. Haseltine W. Letter: Not quite pharmacogenomics. Nature Biotechnology 16 12 (1998) 1295
25. Hedgecoe A. Terminology and the construction of scientific disciplines: The case of pharmacogenomics. Science, Technology and Human Values 28 4 (2003) 513-537
26. Hedgecoe A., and Martin P. The drugs don't work: Expectations and the shaping of pharmacogenetics. Social Studies of Science 33 3 (2003) 327-364
27. Hoffmaster B. Can ethnography save the life of medical ethics?. Social Science and Medicine 35 12 (1992) 1421-1431
28. Hoffmaster B. The forms and limits of medical ethics. Social Science and Medicine 39 9 (1994) 1155-1164
29. Issa A. Ethical considerations in clinical pharmacogenomics research. Trends in Pharmacological Science 21 (2000) 247-249
30. Issa A., and Keyserlingk E. Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: Emerging ethical issues. Canadian Journal of Psychiatry 45 (2000) 917-922
31. Jazwinska E.C. Exploiting human genetic variation in drug discovery and development. Drug Discovery Today 6 4 (2001) 198-205
32. Johnson N., Davis T., and Bosanquet N. The epidemic of Alzheimer's disease. How can we manage the costs?. Pharmacoeconomics 18 3 (2000) 215-223
33. Kumar S. Resisting revolution: Generalism and the new genetics. Lancet 354 (1999) 1992-1993
34. Kumar S., and Gantley M. Tensions between policy makers and general practitioners in implementing new genetics: Grounded theory interview study. British Medical Journal 319 (1999) 1410-1413
35. Levine R. Ethics and regulation of clinical research. 2nd ed. (1988), Yale University Press, New Haven
36. Lindpaintner K. Genetics in drug discovery and development: Challenge and promise of individualizing treatment in common complex disease. British Medical Bulletin 55 2 (1999) 471-491
37. Lindpaintner K., Foot E., Caulfield M., and Hall I. Pharmacogenetics: Focus on pharmacodynamics. International Journal of Pharmaceutical Medicine 15 (2001) 74-82
38. McConnell L.M., Koenig B.A., Greely H.T., and Raffin T.A. Genetic testing and Alzheimer's disease: Has the time come?. Nature Medicine 4 (1998) 757-759
39. McLeod H.L., and Evans W.E. Pharmacogenomics: Unlocking the human genome for better drug therapy. Annual Review of Pharmacology and Toxicology 41 (2001) 101-121
40. Milner, M. (2003). Roche rebuffs new overtures from Novartis. The Guardian, 27 February, 8.
41. Nelson J.L. Moral teachings from unexpected quarters: Lessons for bioethics from the social sciences and managed care. Hastings Center Report 30 (2000) 12-17
42. Noguchi S., Murakami K., and Yamada N. Apolipoprpotein E genotype and Alzheimer's disease. Lancet 342 (1993) 737
43. Nuffield Council on Bioethics. Pharmacogenetics: Ethical issues: Report of working party (2003), Nuffield Council on Bioethics, London
44. Palmer L. Medical liability for pharmacogenomics. In: Rothstein M.A. (Ed). Pharmacogenomics: Social, ethical and clinical dimensions (2003), John Wiley & Sons, New Jersey 187-206
45. Pfost D.R., Boyce-Jacino M.T., and Grant D.M. A SNPshot: Pharmacogenetics and the future of drug therapy. Trends in Biotechnology 18 8 (2000) 334-338
46. Poirier J., Delisle M., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand D., Nalbantoglu J., Gilfix B.M., and Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proceedings of the National Academy of Sciences 92 (1995) 12260-12264
47. Post S.G., Whitehouse P.J., Binstock R.H., Bird T.D., Eckert S.K., Farrer L.A., Fleck L.M., Gaines A.D., Juengst E.T., Karlinsky H., Miles S., Murray T.H., Quaid K.A., Relkin N.R., Roses A.D., St George-Hyslop P.H., Sachs G.A., Steinbock B., Truschke E.F., and Zinn A.B. The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective. Journal of the American Medical Association 277 10 (1997) 832-836
48. Relkin N.R., Kwon Y.J., Tsai J., and Gandy S. Consensus statement: Apolipoprotein E genotyping in Alzheimer's disease. Lancet 347 (1996) 1091-1095
49. Richard F., and Amouyel P. Genetic susceptibility factors for Alzheimer's disease. European Journal of Pharmacology 412 1 (2001) 1-12
50. Rioux P. Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications. American Journal of Health System Pharmacy 57 9 (2000) 887-898
51. Ritchie K., and Dupuy A. The current status of APO E4 as a risk factor for Alzheimer's disease: An epidemiological perspective. International Journal of Geriatric Psychiatry 14 (1999) 695-700
52. Robertson J. Consent and privacy in pharmacogenetic testing. Nature Genetics 28 3 (2001) 207-209
53. Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998). Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease'. Neurobiology of Aging, 19, 109-116.
54. Roses A.D. Pharmacogenetics and the practice of medicine. Nature 405 (2000) 857-865
55. In: Rothstein M.A. (Ed). Pharmacogenomics: Social, ethical and clinical dimensions (2003), John Wiley & Sons, New Jersey
56. Rothstein M.A., and Epps P.G. Ethical and legal implications of pharmacogenomics. Nature Reviews Genetics 2 (2001) 228-231
57. Rusnak J., Kisabeth R., Herbert D., and McNeil D. Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care. Mayo Clinic Proceedings 76 (2001) 299-309
58. Sadee W. Pharmacogenomics. Western Journal of Medicine 171 5/6 (1999) 328-332
59. Saunders A.M., Strittmatter W.J., Schmechel D., Georgehyslop P.H.S., Pericakvance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crappermaclachlan D.R., Alberts M.J., Hulette C., Crain B., Goldgaber D., and Roses A.D. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993) 1467-1472
60. Shi M.M., Bleavins M.R., and de la Iglesia F. Pharmacogenetics application in drug development and clinical trials. Drug Metabolism and Disposition 29 4 (2001) 591-595
61. Smith T. Ethics in medical research (1999), Cambridge University Press, Cambridge
62. Smith R. The failings of NICE. British Medical Journal 321 (2000) 1363-1364
63. Sugarman J., McCrory D.C., Powell D., Krasny A., Adams B., Ball E., and Cassell C. Empirical research on informed consent. An annotated bibliography. The Hastings Center Report 29 1 (1999) S1-S42
64. Sykes, R. (1999). Medical innovation and imperatives. In Proceedings of conference: Getting Better: Developing Mechanisms to Ensure the Best Benefit for Patients from Medical Progress (European Federation of Pharmaceutical Industries and Associations, Brussels, 24 November 1999 (pp. 11-44)) (Available at http://www.efpia.org/6_publ/proceed/getting_better.pdf).
65. Vaszar L.T., Rosen G.D., and Raffin T.A. Pharmacogenomics and the challenge to privacy. The Pharmacogenomics Journal 2 (2002) 144-147
66. Wolf C.R., Smith G., and Smith R.L. Pharmacogenetics. British Medical Journal 320 (2000) 987-990
67. Zussman R. The contribution of sociology to medical ethics. The Hastings Center Report 30 1 (2000) 7-11